RAPT Therapeutics, Inc., a clinical-stage biopharmaceutical company based in South San Francisco, is poised to release topline data from its Phase 2 clinical trial of RPT904 (JYB1904) in patients with Chronic Spontaneous Urticaria (CSU) on October 20, 2025. The trial has been conducted in partnership with Shanghai Jeyou Pharmaceutical Co., Ltd., formerly known as Shanghai Jemincare Pharmaceutical Co., Ltd.
Chronic Spontaneous Urticaria is characterized by the spontaneous appearance of hives, accompanied by intense itching, and can significantly impair quality of life in affected individuals. Current therapeutic options for CSU often have varying degrees of efficacy and potential side effects, underscoring the need for innovative treatment approaches.
RAPT Therapeutics focuses on developing therapies for inflammatory and immunological diseases, and the anticipated results from the Phase 2 trial could provide critical insights into the safety and efficacy profile of RPT904. This investigational compound represents a potential advancement in the therapeutic landscape for CSU.
The company will host a conference call and webcast presentation on October 20, 2025, at 8:30 a.m. ET to share the findings. Participants who wish to join the discussion and partake in a live Q&A session are encouraged to pre-register online to receive the necessary details for accessing the call. The presentation will also be archived for later access on the RAPT Therapeutics website.
As of the date of this announcement, RAPT Therapeutics Inc. shares are trading at $29.34. Despite recent volatility, the company’s stock has demonstrated relative resilience, outperforming market expectations with a slight decline of 1.22% during the current month. Additionally, its performance has been favorable compared to industry peers, indicating a strong interest among investors in the company’s upcoming clinical data.
The upcoming results from the Phase 2 trial are highly anticipated by clinicians, patients, and investors alike, as RAPT Therapeutics continues its mission to deliver new solutions for those suffering from chronic inflammatory conditions.
For further updates and to access the live presentation, stakeholders can visit the RAPT Therapeutics events webpage.
Comments